ALKBH5 downregulates P21 and upregulates MYC protein levels by modulating TACC3 mRNA stability, thereby promoting AML cell proliferation and LSC self‐renewal, which is associated with poor outcomes in AML patients. The gene discussed is TACC3; the disease is acute myeloid leukemia.